{"transactions":[{"id":697247,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock option (right to buy)","published_at":"2026-08-04T12:50:51.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":331000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest and become exercisable with 25% of the shares subject to the award vesting on July 13, 2027 and the remainder vesting in 36 equal monthly installments thereafter, subject to continued service on each such vesting date."}],"balance_after":331000,"derivative":{"exercise_price":64.41,"expiration_date":"2036-08-03","underlying":"Common Stock","underlying_shares":331000},"source":{"system":"sec-edgar","filing":"0001193125-26-331639","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526331639/ownership.xml","form_type":"4"}},{"id":697246,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-08-04T12:50:51.000Z","date":"2026-08-03","kind":"grant","planned":false,"acquired":true,"shares":71000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (\"RSUs\"). 25% of the shares subject to the RSU grant will vest annually over four years, on each July 13, 2027, 2028, 2029 and 2030, subject to continued service on each such vesting date."}],"balance_after":82938,"source":{"system":"sec-edgar","filing":"0001193125-26-331639","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526331639/ownership.xml","form_type":"4"}},{"id":725279,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-27T00:26:57.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":62000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date."}],"balance_after":62000,"derivative":{"exercise_price":4.25,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":62000},"source":{"system":"sec-edgar","filing":"0001470831-26-000670","document":"wk-form4_1782520015.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000147083126000670/wk-form4_1782520015.xml","form_type":"4"}},{"id":748089,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-06-05T11:57:26.000Z","date":"2026-06-04","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company."}],"balance_after":12500,"derivative":{"exercise_price":30.91,"expiration_date":"2036-06-04","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001193125-26-258429","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526258429/ownership.xml","form_type":"4"}},{"id":793903,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-05-04T12:01:56.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":74249,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The grant will vest 50% upon grant date and the remaining 50% in equal monthly installments over a six-month period from the grant date, subject to the Reporting Person's continued services to the Company."}],"balance_after":74249,"derivative":{"exercise_price":29.78,"expiration_date":"2036-05-01","underlying":"Common Stock","underlying_shares":74249},"source":{"system":"sec-edgar","filing":"0001193125-26-202615","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526202615/ownership.xml","form_type":"4"}},{"id":793902,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T12:01:56.000Z","date":"2026-05-01","kind":"grant","planned":false,"acquired":true,"shares":11938,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the grant of restricted stock units (RSUs). The RSUs will vest in full on November 6, 2026, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":11938,"source":{"system":"sec-edgar","filing":"0001193125-26-202615","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526202615/ownership.xml","form_type":"4"}},{"id":802921,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-04-22T12:02:02.000Z","date":"2025-11-22","kind":"grant","planned":false,"acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The grant will vest in equal monthly installments over a one-year period from November 6, 2025, subject to the non-employee director's continued services to the Company."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."}],"balance_after":0,"derivative":{"exercise_price":27.08,"expiration_date":"2035-11-21","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0001193125-26-168530","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526168530/ownership.xml","form_type":"4/A","original_submission_date":"2025-11-25"}},{"id":802919,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2026-04-22T12:01:02.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":33751,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the Company's Non-Employee Director Compensation Policy, these grants were adjusted downward such that the non-employee Director's annual equity compensation in 2025 totals no more than $1,000,000 based on the aggregate grant date fair value as determined in accordance with FASB Topic ASC 718."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The grant will vest in equal monthly installments over a one-year period from the date of grant, subject to the non-employee director's continued services to the Company."}],"balance_after":33751,"derivative":{"exercise_price":24.74,"expiration_date":"2035-11-05","underlying":"Common Stock","underlying_shares":33751},"source":{"system":"sec-edgar","filing":"0001193125-26-168524","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312526168524/ownership.xml","form_type":"4/A","original_submission_date":"2025-11-07"}},{"id":945784,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2026-01-06T21:47:13.000Z","date":"2026-01-02","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2026."}],"balance_after":40000,"derivative":{"exercise_price":8.17,"expiration_date":"2036-01-01","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001533451-26-000002","document":"form4-01062026_090105.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000153345126000002/form4-01062026_090105.xml","form_type":"4"}},{"id":988750,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-11-25T13:50:28.000Z","date":"2025-11-22","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in equal monthly installments over a one-year period from November 6, 2025, subject to the non-employee director's continued services to the Company."}],"balance_after":8000,"derivative":{"exercise_price":27.08,"expiration_date":"2035-11-21","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001193125-25-294675","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312525294675/ownership.xml","form_type":"4"}},{"id":1004918,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-11-07T13:20:09.000Z","date":"2025-11-06","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in equal monthly installments over a one-year period from the date of grant, subject to the non-employee director's continued services to the Company."}],"balance_after":100000,"derivative":{"exercise_price":24.74,"expiration_date":"2035-11-05","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001193125-25-271118","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312525271118/ownership.xml","form_type":"4"}},{"id":1015860,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-10-20T20:44:37.000Z","date":"2025-10-17","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":13.2492,"value":264984.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Shares held by the Steven L Hoerter Revocable Trust dated November 2, 2018, of which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001193125-25-243653","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000119312525243653/ownership.xml","form_type":"4"}},{"id":1104656,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:10:47.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":35500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2026 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date."}],"balance_after":35500,"derivative":{"exercise_price":1.44,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":35500},"source":{"system":"sec-edgar","filing":"0001662579-25-000042","document":"wk-form4_1750450241.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000166257925000042/wk-form4_1750450241.xml","form_type":"4"}},{"id":1119782,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-06-06T12:59:30.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The grant will vest in full on the earlier of the one-year anniversary of the grant date or on the date of our next annual meeting of stockholders, subject to the non-employee director's continued services to the Company."}],"balance_after":16000,"derivative":{"exercise_price":11.86,"expiration_date":"2035-06-05","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-082713","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025082713/ownership.xml","form_type":"4"}},{"id":1174742,"issuer":{"id":4247,"kind":"organization","name":"MBX Biosciences, Inc."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock option (right to buy)","published_at":"2025-04-09T12:27:25.000Z","date":"2025-04-07","kind":"grant","planned":false,"acquired":true,"shares":32000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One-third of the shares underlying this option will vest and become exercisable on April 7, 2026, the anniversary of the date of grant, with the remainder vesting monthly over the subsequent two year period, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":32000,"derivative":{"exercise_price":6,"expiration_date":"2035-04-07","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0000950170-25-052313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1776111/000095017025052313/ownership.xml","form_type":"4"}},{"id":1309794,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-01-06T21:45:43.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":35000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/12th of the shares subject to the option shall vest on each one month anniversary of January 2, 2025."}],"balance_after":35000,"derivative":{"exercise_price":8.26,"expiration_date":"2035-01-01","underlying":"Common Stock","underlying_shares":35000},"source":{"system":"sec-edgar","filing":"0001415889-25-000788","document":"form4-01062025_090139.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000141588925000788/form4-01062025_090139.xml","form_type":"4"}},{"id":1355566,"issuer":{"id":5503,"kind":"organization","name":"C4 Therapeutics, Inc.","symbol":"CCCC"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-21T21:17:11.000Z","date":"2024-11-19","kind":"grant","planned":false,"acquired":true,"shares":65000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"33% of the shares underlying this option shall vest and become exercisable on November 19, 2025, with the remainder vesting in eight equal quarterly installments thereafter, subject to the Reporting Person's continued service on each such vesting date."}],"balance_after":65000,"derivative":{"exercise_price":4.15,"expiration_date":"2034-11-18","underlying":"Common Stock","underlying_shares":65000},"source":{"system":"sec-edgar","filing":"0001662579-24-000108","document":"wk-form4_1732223821.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000166257924000108/wk-form4_1732223821.xml","form_type":"4"}},{"id":1478578,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-06-14T20:24:21.000Z","date":"2024-06-12","kind":"grant","planned":false,"acquired":true,"shares":25600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 12, 2025 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":25600,"derivative":{"exercise_price":7.9,"expiration_date":"2034-06-11","underlying":"Common Stock","underlying_shares":25600},"source":{"system":"sec-edgar","filing":"0001415889-24-016909","document":"form4-06142024_080617.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000141588924016909/form4-06142024_080617.xml","form_type":"4"}},{"id":1483059,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:31:57.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":298100,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":15.92,"underlying":"Common Stock","underlying_shares":298100},"source":{"system":"sec-edgar","filing":"0000950170-24-072196","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017024072196/ownership.xml","form_type":"4"}},{"id":1483058,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:31:57.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":250000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":15.48,"underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0000950170-24-072196","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017024072196/ownership.xml","form_type":"4"}},{"id":1483057,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:31:57.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":415000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":8.27,"underlying":"Common Stock","underlying_shares":415000},"source":{"system":"sec-edgar","filing":"0000950170-24-072196","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017024072196/ownership.xml","form_type":"4"}},{"id":1483056,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:31:57.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":270357,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":9.23,"underlying":"Common Stock","underlying_shares":270357},"source":{"system":"sec-edgar","filing":"0000950170-24-072196","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017024072196/ownership.xml","form_type":"4"}},{"id":1483055,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-12T00:31:57.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":395735,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding stock option of the Issuer having an exercise price per share that is less than the Merger Consideration became fully vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to (A) the number of shares underlying such option multiplied by (B) the Merger Consideration."}],"balance_after":0,"derivative":{"exercise_price":25.4,"underlying":"Common Stock","underlying_shares":395735},"source":{"system":"sec-edgar","filing":"0000950170-24-072196","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017024072196/ownership.xml","form_type":"4"}},{"id":1483054,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-12T00:31:57.000Z","date":"2024-06-11","kind":"other","planned":false,"acquired":false,"shares":72763,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to tax withholding."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-072196","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017024072196/ownership.xml","form_type":"4"}},{"id":1483053,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-12T00:31:57.000Z","date":"2024-06-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":286075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 29, 2024, by and among the Issuer, Ono Pharmaceutical Co., Ltd. (\"Parent\"), and Topaz Merger Sub, Inc., a wholly owned subsidiary of Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.01 per share (the \"Common Stock\") for a price per share of $25.60, without interest and subject to tax withholding (the \"Merger Consideration\"). Effective as of June 11, 2024 (the \"Effective Time\"), Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation in the Merger and as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding RSU (whether vested or unvested) was deemed to have vested, and was cancelled and automatically converted into the right to receive an amount in cash equal to the Merger Consideration."}],"balance_after":72763,"source":{"system":"sec-edgar","filing":"0000950170-24-072196","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017024072196/ownership.xml","form_type":"4"}},{"id":1483052,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-06-12T00:31:57.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":286075,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents restricted stock units (\"RSUs\") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents restricted stock units (\"RSUs\") previously granted to the Reporting Person subject to performance-based vesting conditions, for which the performance conditions associated with such RSUs had not yet occurred."}],"balance_after":358838,"source":{"system":"sec-edgar","filing":"0000950170-24-072196","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017024072196/ownership.xml","form_type":"4"}},{"id":1632735,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-20T21:05:24.000Z","date":"2024-02-15","kind":"grant","planned":false,"acquired":true,"shares":298100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four years, beginning on March 15, 2024."}],"balance_after":298100,"derivative":{"exercise_price":15.92,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":298100},"source":{"system":"sec-edgar","filing":"0000950170-24-017090","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017024017090/ownership.xml","form_type":"4"}},{"id":1710668,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-14T21:05:15.000Z","date":"2023-12-13","kind":"sale","planned":false,"acquired":false,"shares":30664,"price":15.3671,"value":471216.7544,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was to cover tax liabilities in the vesting of RSUs."}],"balance_after":72763,"source":{"system":"sec-edgar","filing":"0000950170-23-070386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017023070386/ownership.xml","form_type":"4"}},{"id":1710667,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-12-14T21:05:15.000Z","date":"2023-12-12","kind":"grant","planned":false,"acquired":true,"shares":62500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 15, 2023, the Reporting Person was granted restricted stock units (\"RSUs\"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 62,500 RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 15, 2023, the Reporting Person was granted restricted stock units (\"RSUs\"), which vest upon the satisfaction of three performance criteria. On December 12, 2023, the Issuer's Compensation Committee confirmed that performance criteria one had been met, resulting in the vesting of 62,500 RSUs."}],"balance_after":103427,"source":{"system":"sec-edgar","filing":"0000950170-23-070386","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000095017023070386/ownership.xml","form_type":"4"}},{"id":1753043,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-31T20:09:14.000Z","date":"2023-10-30","kind":"sale","planned":false,"acquired":false,"shares":21573,"price":12.0176,"value":259255.6848,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was to cover tax liabilities in the vesting of RSUs."}],"balance_after":40927,"source":{"system":"sec-edgar","filing":"0001209191-23-053935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919123053935/doc4.xml","form_type":"4"}},{"id":1753042,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-10-31T20:09:14.000Z","date":"2023-10-28","kind":"grant","planned":false,"acquired":true,"shares":62500,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 15, 2023, the Reporting Person was granted restricted stock units (\"RSUs\"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 62,500 RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On February 15, 2023, the Reporting Person was granted restricted stock units (\"RSUs\"), which vest upon the satisfaction of three performance criteria. On October 28, 2023, the Issuer's Compensation Committee confirmed that performance criteria two had been met, resulting in the vesting of 62,500 RSUs."}],"balance_after":62500,"source":{"system":"sec-edgar","filing":"0001209191-23-053935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919123053935/doc4.xml","form_type":"4"}},{"id":1853943,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-06-15T20:55:24.000Z","date":"2023-06-14","kind":"grant","planned":false,"acquired":true,"shares":20500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) June 14, 2024 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant."}],"balance_after":20500,"derivative":{"exercise_price":6.33,"expiration_date":"2033-06-13","underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001209191-23-037395","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919123037395/doc4.xml","form_type":"4"}},{"id":1939986,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-03-23T20:05:22.000Z","date":"2023-03-21","kind":"sale","planned":false,"acquired":false,"shares":7500,"price":15.5709,"value":116781.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2019, the Reporting Person was granted 30,000 Restricted Stock Units (\"RSUs\") which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.395 to $15.70, inclusive. The Reporting Person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-23-020720","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919123020720/doc4.xml","form_type":"4"}},{"id":2010509,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-02-16T21:18:46.000Z","date":"2023-02-15","kind":"grant","acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on March 15, 2023."}],"balance_after":250000,"derivative":{"exercise_price":15.48,"expiration_date":"2033-02-14","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001209191-23-010062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919123010062/doc4.xml","form_type":"4"}},{"id":2010508,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-02-16T21:18:46.000Z","date":"2023-02-14","kind":"sale","acquired":false,"shares":30045,"price":16,"value":480720.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 14, 2022."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001209191-23-010062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919123010062/doc4.xml","form_type":"4"}},{"id":2226976,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-06-18T00:20:43.000Z","date":"2022-06-17","kind":"grant","acquired":true,"shares":50283,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"(A) 17,083 of the shares subject to the option shall vest on the earlier of (i) June 17, 2023 or (ii) the business day prior to the next annual meeting of the Issuer's stockholders that occurs following the date of grant, and (B)  one thirty-sixth (1/36th) of the remaining 33,200 shares subject to the option shall vest on each monthly anniversary of June 17, 2022."}],"balance_after":50283,"derivative":{"exercise_price":3.75,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":50283},"source":{"system":"sec-edgar","filing":"0001209191-22-038199","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919122038199/doc4.xml","form_type":"4"}},{"id":2319796,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2022-03-23T20:15:25.000Z","date":"2022-03-21","kind":"tax_withholding","acquired":false,"shares":3150,"price":9.11,"value":28696.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2019, the Reporting Person was granted 30,000 Restricted Stock Units (\"RSUs\") which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2021 to cover tax obligations."}],"balance_after":37545,"source":{"system":"sec-edgar","filing":"0001209191-22-020765","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919122020765/doc4.xml","form_type":"4"}},{"id":2429897,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-20T22:00:12.000Z","date":"2022-01-18","kind":"grant","acquired":false,"shares":415000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan.  The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022."}],"balance_after":415000,"derivative":{"exercise_price":8.27,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":415000},"source":{"system":"sec-edgar","filing":"0001209191-22-004073","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919122004073/doc4.xml","form_type":"4"}},{"id":2465460,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-12-17T21:10:18.000Z","date":"2021-12-15","kind":"grant","acquired":true,"shares":270357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan (the \"2017 Plan\").  The option shall vest in two equal installments on June 15, 2022 and June 15, 2023, subject to continuous service with the Issuer or a Subsidiary (as defined in the 2017 Plan) through each vesting date."}],"balance_after":270357,"derivative":{"exercise_price":9.23,"expiration_date":"2031-12-14","underlying":"Common Stock","underlying_shares":270357},"source":{"system":"sec-edgar","filing":"0001209191-21-070248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919121070248/doc4.xml","form_type":"4"}},{"id":2601906,"issuer":{"id":4765,"kind":"organization","name":"Oric Pharmaceuticals, Inc.","symbol":"ORIC"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-08-16T21:56:04.000Z","date":"2021-08-13","kind":"grant","acquired":true,"shares":33250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One thirty-sixth (1/36th) of the shares subject to the option shall vest on each monthly anniversary of August 13, 2021."}],"balance_after":33250,"derivative":{"exercise_price":18.63,"expiration_date":"2031-08-12","underlying":"Common Stock","underlying_shares":33250},"source":{"system":"sec-edgar","filing":"0001209191-21-051657","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919121051657/doc4.xml","form_type":"4"}},{"id":2625829,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-23T16:27:58.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":26342,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":9.05,"underlying":"Common Stock","underlying_shares":26342},"source":{"system":"sec-edgar","filing":"0001562180-21-005057","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021005057/primarydocument.xml","form_type":"4/A","original_submission_date":"2021-07-19"}},{"id":2630273,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2021-07-19T17:35:12.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":13171,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":37.52,"underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0001562180-21-004982","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004982/primarydocument.xml","form_type":"4"}},{"id":2630272,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-19T17:35:12.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":26342,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":7.6,"underlying":"Common Stock","underlying_shares":26342},"source":{"system":"sec-edgar","filing":"0001562180-21-004982","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004982/primarydocument.xml","form_type":"4"}},{"id":2630271,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-07-19T17:35:12.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":13171,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":9.12,"underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0001562180-21-004982","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004982/primarydocument.xml","form_type":"4"}},{"id":2630270,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-07-19T17:35:12.000Z","date":"2021-07-15","kind":"disposition_to_issuer","acquired":false,"shares":13171,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"This Form 4 reports securities disposed of under the terms of the Agreement and Plan of Merger (the ''Agreement''), dated as of June 2, 2021, among Constellation Pharmaceuticals, Inc. (the \"Company\"), MorphoSys AG (\"Parent\") and MorphoSys Development Inc. (\"Purchaser\"), an indirect wholly owned subsidiary of Parent. Pursuant to the Agreement, on July 15, 2021 (the \"Effective Time\"), Purchaser merged with and into the Company, with the Company becoming a wholly owned subsidiary of Parent (the \"Merger\").  In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.0001 per share, of the Company (\"Common Stock\") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was converted into the right to receive $34.00 in cash, without interest and subject to any required withholding of taxes (the \"Merger Consideration\")."}],"balance_after":0,"derivative":{"exercise_price":33.57,"underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0001562180-21-004982","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004982/primarydocument.xml","form_type":"4"}},{"id":2680825,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-04T16:56:16.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":13171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 2, 2021, and the shares underlying the option vest in equal quarterly installments through June 2, 2022, subject to continued service."}],"balance_after":13171,"derivative":{"exercise_price":33.57,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0001562180-21-004073","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218021004073/primarydocument.xml","form_type":"4"}},{"id":2776008,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-22T21:00:12.000Z","date":"2021-03-18","kind":"tax_withholding","acquired":false,"shares":2450,"price":43.1949,"value":105827.505,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2019, was granted 30,000 Restricted Stock Units (RSUs) which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported in this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 25, 2020 to cover tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.02 to $43.58, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":40695,"source":{"system":"sec-edgar","filing":"0001209191-21-022386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919121022386/doc4.xml","form_type":"4"}},{"id":2776007,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-03-22T21:00:12.000Z","date":"2021-03-18","kind":"tax_withholding","acquired":false,"shares":700,"price":42.3886,"value":29672.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2019, was granted 30,000 Restricted Stock Units (RSUs) which vest in four (4) equal annual installments beginning on March 18, 2020. These RSUs were reported in Table I on a Form 4 filed on March 20, 2019. The sale of shares reported in this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 25, 2020 to cover tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.95 to $42.73, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":43145,"source":{"system":"sec-edgar","filing":"0001209191-21-022386","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919121022386/doc4.xml","form_type":"4"}},{"id":2849006,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-02-18T23:08:19.000Z","date":"2021-02-16","kind":"grant","acquired":false,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan.  The option shall vest in equal monthly installments over four years, beginning on March 16, 2021."}],"balance_after":210000,"derivative":{"exercise_price":47.79,"expiration_date":"2031-02-15","underlying":"Common Stock","underlying_shares":210000},"source":{"system":"sec-edgar","filing":"0001209191-21-012049","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919121012049/doc4.xml","form_type":"4"}},{"id":2897372,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-25T22:00:10.000Z","date":"2021-01-21","kind":"exercise","acquired":false,"shares":1078,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options vested on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":395735,"derivative":{"exercise_price":25.4,"expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":1078},"source":{"system":"sec-edgar","filing":"0001209191-21-005106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919121005106/doc4.xml","form_type":"4"}},{"id":2897371,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2021-01-25T22:00:10.000Z","date":"2021-01-21","kind":"exercise","acquired":true,"shares":1078,"price":25.4,"value":27381.2,"ownership":{"direct":true},"balance_after":43845,"source":{"system":"sec-edgar","filing":"0001209191-21-005106","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919121005106/doc4.xml","form_type":"4"}},{"id":3048416,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-08-24T20:00:57.000Z","date":"2020-08-20","kind":"exercise","acquired":false,"shares":187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options vested on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":396813,"derivative":{"exercise_price":25.4,"expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":187},"source":{"system":"sec-edgar","filing":"0001209191-20-048062","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120048062/doc4.xml","form_type":"4"}},{"id":3048415,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-08-24T20:00:57.000Z","date":"2020-08-20","kind":"exercise","acquired":true,"shares":187,"price":25.4,"value":4749.8,"ownership":{"direct":true},"balance_after":42767,"source":{"system":"sec-edgar","filing":"0001209191-20-048062","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120048062/doc4.xml","form_type":"4"}},{"id":3077574,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-22T20:00:09.000Z","date":"2020-07-20","kind":"exercise","acquired":false,"shares":188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options vested on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":397000,"derivative":{"exercise_price":25.4,"expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":188},"source":{"system":"sec-edgar","filing":"0001209191-20-043295","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120043295/doc4.xml","form_type":"4"}},{"id":3077573,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-07-22T20:00:09.000Z","date":"2020-07-20","kind":"exercise","acquired":true,"shares":188,"price":25.4,"value":4775.2,"ownership":{"direct":true},"balance_after":42580,"source":{"system":"sec-edgar","filing":"0001209191-20-043295","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120043295/doc4.xml","form_type":"4"}},{"id":3103995,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-19T20:00:12.000Z","date":"2020-06-18","kind":"grant","acquired":false,"shares":187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options vested on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":397188,"derivative":{"exercise_price":25.4,"expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":187},"source":{"system":"sec-edgar","filing":"0001209191-20-037893","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120037893/doc4.xml","form_type":"4"}},{"id":3103994,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-19T20:00:12.000Z","date":"2020-06-18","kind":"exercise","acquired":true,"shares":187,"price":25.4,"value":4749.8,"ownership":{"direct":true},"balance_after":42392,"source":{"system":"sec-edgar","filing":"0001209191-20-037893","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120037893/doc4.xml","form_type":"4"}},{"id":3118582,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2020-06-08T18:15:57.000Z","date":"2020-06-04","kind":"grant","acquired":true,"shares":13171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 4, 2020, and the shares underlying the option vest in equal quarterly installments through June 4, 2021, subject to continued service."}],"balance_after":13171,"derivative":{"exercise_price":37.52,"expiration_date":"2030-06-04","underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0001562180-20-004334","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000156218020004334/primarydocument.xml","form_type":"4"}},{"id":3128766,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-01T20:05:13.000Z","date":"2020-05-28","kind":"grant","acquired":false,"shares":188,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options vested on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":397375,"derivative":{"exercise_price":25.4,"expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":188},"source":{"system":"sec-edgar","filing":"0001209191-20-033175","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120033175/doc4.xml","form_type":"4"}},{"id":3128765,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-06-01T20:05:13.000Z","date":"2020-05-28","kind":"exercise","acquired":true,"shares":188,"price":25.4,"value":4775.2,"ownership":{"direct":true},"balance_after":42205,"source":{"system":"sec-edgar","filing":"0001209191-20-033175","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120033175/doc4.xml","form_type":"4"}},{"id":3170882,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-04-23T20:10:12.000Z","date":"2020-04-21","kind":"grant","acquired":false,"shares":187,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options vested on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":397563,"derivative":{"exercise_price":25.4,"expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":187},"source":{"system":"sec-edgar","filing":"0001209191-20-025420","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120025420/doc4.xml","form_type":"4"}},{"id":3170881,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-04-23T20:10:12.000Z","date":"2020-04-21","kind":"exercise","acquired":true,"shares":187,"price":25.4,"value":4749.8,"ownership":{"direct":true},"balance_after":42017,"source":{"system":"sec-edgar","filing":"0001209191-20-025420","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120025420/doc4.xml","form_type":"4"}},{"id":3198952,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T21:49:06.000Z","date":"2019-03-18","kind":"grant","acquired":false,"shares":2250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":397750,"derivative":{"exercise_price":25.4,"expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":2250},"source":{"system":"sec-edgar","filing":"0001209191-20-020507","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120020507/doc4.xml","form_type":"4"}},{"id":3198951,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-20T21:49:06.000Z","date":"2020-03-19","kind":"tax_withholding","acquired":false,"shares":520,"price":39.98,"value":20789.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2019 the Reporting Person was granted 22,000 Restricted Stock Units (RSUs) which vested in full on March 18, 2020 and was granted 30,000 RSUs which vest in four (4) equal annual installments beginning on March 18, 2020.  These RSUs were reported in Table I on a Form 4 filed on March 20, 2019.  The sale of shares reported in this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.88 to $40.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":41830,"source":{"system":"sec-edgar","filing":"0001209191-20-020507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120020507/doc4.xml","form_type":"4"}},{"id":3198950,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-20T21:49:06.000Z","date":"2020-03-19","kind":"tax_withholding","acquired":false,"shares":2164,"price":39.22,"value":84872.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2019 the Reporting Person was granted 22,000 Restricted Stock Units (RSUs) which vested in full on March 18, 2020 and was granted 30,000 RSUs which vest in four (4) equal annual installments beginning on March 18, 2020.  These RSUs were reported in Table I on a Form 4 filed on March 20, 2019.  The sale of shares reported in this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.77, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":42350,"source":{"system":"sec-edgar","filing":"0001209191-20-020507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120020507/doc4.xml","form_type":"4"}},{"id":3198949,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-20T21:49:06.000Z","date":"2020-03-19","kind":"tax_withholding","acquired":false,"shares":4230,"price":38.26,"value":161839.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2019 the Reporting Person was granted 22,000 Restricted Stock Units (RSUs) which vested in full on March 18, 2020 and was granted 30,000 RSUs which vest in four (4) equal annual installments beginning on March 18, 2020.  These RSUs were reported in Table I on a Form 4 filed on March 20, 2019.  The sale of shares reported in this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.77 to $38.76, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":44514,"source":{"system":"sec-edgar","filing":"0001209191-20-020507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120020507/doc4.xml","form_type":"4"}},{"id":3198948,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-20T21:49:06.000Z","date":"2020-03-19","kind":"tax_withholding","acquired":false,"shares":1012,"price":36.88,"value":37322.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2019 the Reporting Person was granted 22,000 Restricted Stock Units (RSUs) which vested in full on March 18, 2020 and was granted 30,000 RSUs which vest in four (4) equal annual installments beginning on March 18, 2020.  These RSUs were reported in Table I on a Form 4 filed on March 20, 2019.  The sale of shares reported in this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.73 to $37.24, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":48744,"source":{"system":"sec-edgar","filing":"0001209191-20-020507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120020507/doc4.xml","form_type":"4"}},{"id":3198947,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-20T21:49:06.000Z","date":"2020-03-19","kind":"tax_withholding","acquired":false,"shares":4494,"price":35.78,"value":160795.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 18, 2019 the Reporting Person was granted 22,000 Restricted Stock Units (RSUs) which vested in full on March 18, 2020 and was granted 30,000 RSUs which vest in four (4) equal annual installments beginning on March 18, 2020.  These RSUs were reported in Table I on a Form 4 filed on March 20, 2019.  The sale of shares reported in this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person to cover tax obligations."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.27 to $36.01, inclusive. The reporting person undertakes to provide to Deciphera Pharmaceuticals, Inc., any security holder of Deciphera Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":49756,"source":{"system":"sec-edgar","filing":"0001209191-20-020507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120020507/doc4.xml","form_type":"4"}},{"id":3198946,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2020-03-20T21:49:06.000Z","date":"2020-03-18","kind":"exercise","acquired":true,"shares":2250,"price":25.4,"value":57150.0,"ownership":{"direct":true},"balance_after":54250,"source":{"system":"sec-edgar","filing":"0001209191-20-020507","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120020507/doc4.xml","form_type":"4"}},{"id":3258905,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-02-20T21:10:11.000Z","date":"2020-02-18","kind":"grant","acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option award was issued pursuant to Issuer's 2017 Stock Option and Incentive Plan. The option vests in 48 equal monthly installments over a 4-year period following the vesting commencement date of 2/18/2020, subject to continued service through such dates."}],"balance_after":180000,"derivative":{"exercise_price":54.87,"expiration_date":"2030-02-17","underlying":"Common Stock","underlying_shares":180000},"source":{"system":"sec-edgar","filing":"0001209191-20-011039","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919120011039/doc4.xml","form_type":"4"}},{"id":3495650,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2019-06-10T16:50:11.000Z","date":"2019-06-06","kind":"grant","acquired":true,"shares":13171,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on June 6, 2019 and will vest as to all shares underlying the option on June 6, 2020, subject to continued service."}],"balance_after":13171,"derivative":{"exercise_price":9.12,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":13171},"source":{"system":"sec-edgar","filing":"0000899243-19-016210","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000089924319016210/doc4.xml","form_type":"4"}},{"id":3584330,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President  & CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-20T21:47:39.000Z","date":"2019-03-18","kind":"grant","acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. 25% of the options shall vest on March 18, 2020, and the remaining options shall vest in equal monthly installments over the following three years, subject to continued service through such dates."}],"balance_after":400000,"derivative":{"exercise_price":25.4,"expiration_date":"2029-03-17","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001209191-19-020631","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919119020631/doc4.xml","form_type":"4"}},{"id":3584329,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President  & CEO"}}],"security":"Common Stock","published_at":"2019-03-20T21:47:39.000Z","date":"2019-03-18","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reporting person was awarded 30,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in four (4) equal annual installments beginning on March 18, 2020, subject to the reporting person's continuous service with the Company through such dates. The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":52000,"source":{"system":"sec-edgar","filing":"0001209191-19-020631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919119020631/doc4.xml","form_type":"4"}},{"id":3584328,"issuer":{"id":90033,"kind":"organization","name":"Deciphera Pharmaceuticals, Inc.","symbol":"NA"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President  & CEO"}}],"security":"Common Stock","published_at":"2019-03-20T21:47:39.000Z","date":"2019-03-18","kind":"grant","acquired":true,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person was awarded 22,000 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's Common Stock. The Restricted Stock Units shall vest in full on March 18, 2020, subject to the reporting person's continuous service with the Company through such date.  The Restricted Stock Units may be settled only by delivering shares of the Issuer's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":22000,"source":{"system":"sec-edgar","filing":"0001209191-19-020631","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1533451/000120919119020631/doc4.xml","form_type":"4"}},{"id":3611975,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-05T21:04:05.000Z","date":"2019-03-04","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":50650,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-19-016381","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/doc4.xml","form_type":"4"}},{"id":3611974,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2019-03-05T21:04:05.000Z","date":"2019-03-01","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":55650,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001209191-19-016381","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/doc4.xml","form_type":"4"}},{"id":3611973,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2019-03-05T21:04:05.000Z","date":"2019-03-04","kind":"sale","acquired":false,"shares":5000,"price":68,"value":340000.0,"ownership":{"direct":true},"balance_after":10941,"source":{"system":"sec-edgar","filing":"0001209191-19-016381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/doc4.xml","form_type":"4"}},{"id":3611972,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2019-03-05T21:04:05.000Z","date":"2019-03-04","kind":"exercise","acquired":true,"shares":5000,"price":39.76,"value":198800.0,"ownership":{"direct":true},"balance_after":15941,"source":{"system":"sec-edgar","filing":"0001209191-19-016381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/doc4.xml","form_type":"4"}},{"id":3611971,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2019-03-05T21:04:05.000Z","date":"2019-03-01","kind":"sale","acquired":false,"shares":5000,"price":66.01,"value":330050.0,"ownership":{"direct":true},"balance_after":10941,"source":{"system":"sec-edgar","filing":"0001209191-19-016381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/doc4.xml","form_type":"4"}},{"id":3611970,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2019-03-05T21:04:05.000Z","date":"2019-03-01","kind":"exercise","acquired":true,"shares":5000,"price":39.76,"value":198800.0,"ownership":{"direct":true},"balance_after":15941,"source":{"system":"sec-edgar","filing":"0001209191-19-016381","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119016381/doc4.xml","form_type":"4"}},{"id":3645714,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Restricted stock units","published_at":"2019-02-20T21:06:35.000Z","date":"2019-02-16","kind":"exercise","acquired":false,"shares":2750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on February 16, 2018. Beginning on February 16, 2019, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":5500,"derivative":{"underlying":"Common stock","underlying_shares":2750},"source":{"system":"sec-edgar","filing":"0001209191-19-011494","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011494/doc4.xml","form_type":"4"}},{"id":3645713,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2019-02-20T21:06:35.000Z","date":"2019-02-19","kind":"tax_withholding","acquired":false,"shares":1040,"price":58.03,"value":60351.2,"ownership":{"direct":true},"balance_after":10941,"source":{"system":"sec-edgar","filing":"0001209191-19-011494","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011494/doc4.xml","form_type":"4"}},{"id":3645712,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2019-02-20T21:06:35.000Z","date":"2019-02-16","kind":"exercise","acquired":true,"shares":2750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":11981,"source":{"system":"sec-edgar","filing":"0001209191-19-011494","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119011494/doc4.xml","form_type":"4"}},{"id":3689311,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share unit","published_at":"2019-01-23T21:19:38.000Z","date":"2019-01-20","kind":"exercise","acquired":false,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance share units were originally granted on February 16, 2016. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance share units were originally granted on February 16, 2016. The performance share units vest in full six months after the achievement of performance milestone. Performance milestone was achieved on July 20, 2018, and the performance share will vest in full on January 20, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-19-004955","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119004955/doc4.xml","form_type":"4"}},{"id":3689310,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2019-01-23T21:19:38.000Z","date":"2019-01-22","kind":"tax_withholding","acquired":false,"shares":5769,"price":52.82,"value":304718.58,"ownership":{"direct":true},"balance_after":9231,"source":{"system":"sec-edgar","filing":"0001209191-19-004955","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119004955/doc4.xml","form_type":"4"}},{"id":3689309,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2019-01-23T21:19:38.000Z","date":"2019-01-20","kind":"exercise","acquired":true,"shares":15000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-19-004955","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919119004955/doc4.xml","form_type":"4"}},{"id":3825314,"issuer":{"id":137050,"kind":"organization","name":"CONSTELLATION PHARMACEUTICALS INC","symbol":"CNST"},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2018-09-05T17:44:03.000Z","date":"2018-09-04","kind":"grant","acquired":true,"shares":26342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on September 4, 2018 and is scheduled to vest in equal monthly installments through September 4, 2021, subject to continued service."}],"balance_after":26342,"derivative":{"exercise_price":9.05,"expiration_date":"2028-09-03","underlying":"Common Stock","underlying_shares":26342},"source":{"system":"sec-edgar","filing":"0000899243-18-023861","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1434418/000089924318023861/doc4.xml","form_type":"4"}},{"id":3831542,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-08-28T20:06:58.000Z","date":"2018-08-24","kind":"exercise","acquired":false,"shares":2050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":60650,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":2050},"source":{"system":"sec-edgar","filing":"0001209191-18-048672","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118048672/doc4.xml","form_type":"4"}},{"id":3831541,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2018-08-28T20:06:58.000Z","date":"2018-08-24","kind":"sale","acquired":false,"shares":2050,"price":74.92,"value":153586.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-048672","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118048672/doc4.xml","form_type":"4"}},{"id":3831540,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2018-08-28T20:06:58.000Z","date":"2018-08-24","kind":"exercise","acquired":true,"shares":2050,"price":39.76,"value":81508.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2050,"source":{"system":"sec-edgar","filing":"0001209191-18-048672","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118048672/doc4.xml","form_type":"4"}},{"id":3859912,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-07-27T20:01:16.000Z","date":"2018-07-25","kind":"exercise","acquired":false,"shares":2050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":62700,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":2050},"source":{"system":"sec-edgar","filing":"0001209191-18-044183","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118044183/doc4.xml","form_type":"4"}},{"id":3859911,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2018-07-27T20:01:16.000Z","date":"2018-07-25","kind":"sale","acquired":false,"shares":2050,"price":84.58,"value":173389.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-044183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118044183/doc4.xml","form_type":"4"}},{"id":3859910,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2018-07-27T20:01:16.000Z","date":"2018-07-25","kind":"exercise","acquired":true,"shares":2050,"price":39.76,"value":81508.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2050,"source":{"system":"sec-edgar","filing":"0001209191-18-044183","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118044183/doc4.xml","form_type":"4"}},{"id":3862197,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Performance share units","published_at":"2018-07-24T20:37:13.000Z","date":"2018-07-20","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each performance share unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The performance share units were originally granted on February 16, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The performance share units were originally granted on February 16, 2016. The performance share units vest in full six months after the achievement of a performance milestone. The performance milestone was achieved on July 20, 2018, and the performance share units will vest in full on January 20, 2019.  Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":15000,"derivative":{"underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001209191-18-043734","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118043734/doc4.xml","form_type":"4"}},{"id":3882973,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-06-26T20:02:51.000Z","date":"2018-06-22","kind":"exercise","acquired":false,"shares":2050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":64750,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":2050},"source":{"system":"sec-edgar","filing":"0001209191-18-039501","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118039501/doc4.xml","form_type":"4"}},{"id":3882972,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2018-06-26T20:02:51.000Z","date":"2018-06-22","kind":"sale","acquired":false,"shares":2050,"price":97.58,"value":200039.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-039501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118039501/doc4.xml","form_type":"4"}},{"id":3882971,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2018-06-26T20:02:51.000Z","date":"2018-06-22","kind":"exercise","acquired":true,"shares":2050,"price":39.76,"value":81508.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2050,"source":{"system":"sec-edgar","filing":"0001209191-18-039501","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118039501/doc4.xml","form_type":"4"}},{"id":3915363,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Stock option (right to buy)","published_at":"2018-05-29T10:14:49.000Z","date":"2018-05-23","kind":"exercise","acquired":false,"shares":2050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on February 16, 2016. The shares underlying this option vest as to 25% of the underlying shares on February 16, 2017, with the remaining 75% vesting in 36 equal monthly installments thereafter."}],"balance_after":66800,"derivative":{"exercise_price":39.76,"expiration_date":"2026-02-15","underlying":"Common stock","underlying_shares":2050},"source":{"system":"sec-edgar","filing":"0001209191-18-033648","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118033648/doc4.xml","form_type":"4"}},{"id":3915362,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2018-05-29T10:14:49.000Z","date":"2018-05-23","kind":"sale","acquired":false,"shares":2050,"price":85.76,"value":175808.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001209191-18-033648","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118033648/doc4.xml","form_type":"4"}},{"id":3915361,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":26666,"kind":"person","name":"Hoerter Steven L.","position":1,"cik":"0001533451","reported_name":"Hoerter Steven L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Commercial Officer"}}],"security":"Common stock","published_at":"2018-05-29T10:14:49.000Z","date":"2018-05-23","kind":"exercise","acquired":true,"shares":2050,"price":39.76,"value":81508.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":2050,"source":{"system":"sec-edgar","filing":"0001209191-18-033648","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1439222/000120919118033648/doc4.xml","form_type":"4"}}],"next_cursor":"2018-05-29T10:14:49.000000Z,3915361"}